Abstract
In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.
Original language | English |
---|---|
Journal | Nature Reviews Clinical Oncology |
DOIs | |
Publication status | Accepted/In press - Jan 1 2018 |
ASJC Scopus subject areas
- Oncology